C Reactive Protein Testing Market

Market Overview

The global C reactive protein testing market size was valued at USD 5.54 billion in 2022. It is estimated to reach USD 5.69 billion by 2031, growing at a CAGR of 0.3% during the forecast period (2023–2031). The market growth is anticipated to be boosted by the increased frequency of chronic diseases and increasing R&D in C-reactive protein testing.

A c-reactive protein test measures the amount of c-reactive protein (CRP) in a blood sample. The liver produces the protein CRP. C-reactive protein levels in the blood are typically low. If there is inflammation throughout the body, the liver releases more CRP into the bloodstream. Having a significant health issue that generates inflammation and high levels of CRP could be a sign of that. A CRP test can reveal whether and how much inflammation exists in the body. The test, however, cannot determine what is causing the inflammation or which area of your body is affected. A CRP test may detect or track inflammation in short-term or long-term illnesses, such as Viral or bacterial infections; disorders of the intestines, such as Crohn's disease and ulcerative colitis, are examples of "inflammatory bowel disease." Vasculitis, lupus, and rheumatoid arthritis are examples of autoimmune diseases and lung conditions like asthma.

Market Dynamics

Global  C Reactive Protein Testing Market Drivers

Increasing R&D in the Field of C-reactive protein Testing

One of the key factors influencing the market is the extensive research being done in this area. Diverse governmental and private entities fund these research initiatives. Additionally, creating point-of-care diagnostics that enable patients to do CRP testing is anticipated to accelerate market expansion shortly. For instance, portable and user-friendly paper-based diagnostics have been introduced to detect C-reactive proteins. The wax method is the foundation of paper-based CRP testing equipment. This method lowers the cost of testing's overall operation and production by defining hydrophobic boundaries for fluidic and point-of-care devices.

However, in many poor regions, it is challenging to apply such technologies. The serum stain length can be measured using these paper-based experiments inside the paper-micro channel. These tests typically take five minutes for each assay, as opposed to the three to four hours required by conventional lab-based CRP assays. National Tsing Hua University funded this project in collaboration with other organizations in 2016. Over the forecast period, such changes in the industry are anticipated to fuel technological improvements in the CRP testing market.

Rising Incidence of Chronic Disorders

The primary factor anticipated to propel the market for CRP testing during the forecast period is an increase in inflammatory illnesses worldwide. The National Center for Health Statistics estimates that 690,882 people in the United States alone will die from heart-related illnesses in 2020. The most prevalent form of cardiovascular disease, coronary heart disease, causes 370,000 fatalities each year. The American Heart Association estimates that around 121.5 million adults in the United States have cardiovascular disease. By 2035, it is anticipated that over 130 million adults in the United States will have a kind of heart disease.

Additionally, about 25% of cancer cases worldwide are brought on by cancer-causing diseases such as hepatitis and the Human Papillomavirus (HPV). The most prevalent form of cancer, lung cancer, kills 1.69 million people annually, followed by liver cancer (788,000 deaths), colorectal cancer (744,000 deaths), and liver cancer (788,000 deaths). The idea that CRP testing aids in determining the risk of chronic inflammation linked to malignancies is supported by several research. Additionally, increasing endometriosis incidences in females are anticipated to fuel the CRP testing market during the anticipated time frame. Endometriosis affects more than 10 million women worldwide, which is predicted to rise in the future. Over the projected period, the market growth is anticipated to be boosted by the increased frequency of chronic diseases.

Global  C Reactive Protein Testing Market Restraint

Availability of Alternative Disease Testing Methods

Alternative testing methods' accessibility is anticipated to impede the market's expansion for CRP testing. Numerous blood tests, including creatine kinase, myoglobin, cardiac troponin I or T, and creatine kinase-MB, are available to identify cardiovascular diseases. These tests look for protein imbalances in the body, which are linked to heart conditions. Tests based on cardiac troponin are more specific and sensitive to heart diseases. Additionally, some tests enable quantifying triglycerides, LDL, HDL levels, and cholesterol, which are essential for managing cardiac risk and identifying heart inflammations.

Additionally, it is anticipated that ongoing work on innovative diagnostics and the availability of competing immunoprotein-based tests on the market may restrain the market expansion for CRP tests. In addition, testing for plasma viscosity (PV) and erythrocyte sedimentation rate (ESR) are utilized to identify inflammatory illnesses in individuals. ESR tests are less precise than PV testing, however. Thus, it is projected that the availability of several alternatives to CRP tests may restrain market growth throughout the projection period.

Global  C Reactive Protein Testing Market Opportunities

Technological Advancements in Conventional CRP Tests

CRP has evolved as a versatile diagnostic for identifying systemic inflammatory diseases. The development of CRP tests with improved sensitivity and specificity has followed developments in nanomaterials and electroanalytical chemistry. A gradual transition from traditional antigen-antibody interactions to CRP-based enzymatic tests with contemporary electrochemical biosensors is one of the advancements in CRP testing. A highly sensitive, portable detection system based on ZnS nanoparticle, metal-oxide-semiconductor field-effect transistor/bipolar junction transistor, aptamer, silicon nanowire, vertical flow immunoassay, field emission transmitter, and other nanomaterials is developed using electrochemical sensors.

Future developments in interdisciplinary techniques are anticipated to enable an ultrasensitive analysis of CRP levels in a lot less time. As a result, more people would use CRP testing techniques to identify systemic inflammatory diseases. Additionally, there are significant opportunities in the CRP testing industry for new CRP identification compounds and materials that support the development of sensing platforms.

Regional Analysis

Based on region, the global C reactive protein testing market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America is the most significant global C reactive protein testing market shareholder and is estimated to exhibit a CAGR of 0.17% over the forecast period. In 2020, North America held the greatest market share. This can be linked to several things, including the region's strong R&D spending, favorable government policies, and well-established healthcare infrastructure. Another important element driving the market's expansion is the increased prevalence of malignancies and chronic cardiac illnesses. The use of the test for the first screening of various inflammatory disorders is made more popular by the presence of organizations like the American College of Cardiology Foundation and others of a like nature. These organizations publish news releases through employee screening programs and run awareness campaigns on social media and among private groups.

Other important market drivers include the presence of significant market participants locally, the accessibility of various testing kits and reagents, and rising public awareness of early illness testing and screening. However, the test prices have decreased due to the market's increased pricing pressure on established market players. This may limit market expansion in the area over the anticipated time frame.

Europe is anticipated to exhibit a CAGR of 0.32% over the forecast period. Regional expansion is anticipated to be fueled by increasing rates of heat-related illnesses in the area, supporting government policies, partnerships between public and private market players, and ongoing regional research. The industry is also expected to be driven by funding for R&D received from various international agencies, such as the NIH and WHO. A significant public health burden in the European Union is cancer. According to the WHO, the European region has more than 1.9 million cancer-related fatalities and 3.7 million new cases each year; as a result, there is a need for widespread use of POC CRP testing technologies to help with cancer management in the European region. Furthermore, the need for CRP testing services and products is anticipated to increase significantly shortly due to the rapid spread of COVID-19 infection throughout European countries.

Asia-Pacific has emerged as one of the fastest-growing regions in the global market. Even if there isn't much development and expansion in the worldwide market, Asia Pacific is predicted to grow at the highest rate. The rise in the number of geriatrics in the area, the prevalence of chronic diseases, and the number of studies on CRP testing are all contributing factors to the market's expansion. Additionally, the industry is progressing due to favorable government policies, an advanced healthcare infrastructure, and partnerships between public and private market participants.

Furthermore, it is anticipated that the study on the patterns of weight increase in Chinese people related to elevated C-reactive protein levels would further propel market advancements. The region is anticipated to experience tremendous growth potential due to rising government and private sector activities.

In Latin America, Healthcare businesses looking for operational efficiency, market access, attractive demographics, low-cost land and labor, and innovation routes have been eyeing Latin America. Due to government reforms for early cancer identification, free medical and hospital care, and increased research funding, the CRP testing industry in the region has great growth potential. Latin American governments have stabilized and signed liberal trade deals. Drug and treatment demand is rising as healthcare support and middle-class populations rise. In 2020, cardiovascular, cancer, and chronic respiratory disorders caused 81% of fatalities, according to the Population Reference Bureau. Obesity and smoking are major causes of these diseases in this region. Non-communicable diseases kill many people prematurely, especially men. Thus, more testing processes are undertaken, driving market expansion. Latin American nations offer affordable testing and diagnosis. These variables will likely increase CRP testing demand in the region.

The Middle East and Africa held the smallest market share in 2020 due to a developing healthcare system and poor POC CRP testing equipment knowledge. However, the market is anticipated to be driven by rising rates of chronic diseases in the area and increased R&D research. The lack of inexpensive treatment choices, the underdeveloped healthcare infrastructure, and the limited availability of innovative diagnostic methods make the Middle East and Africa an attractive investment target for major manufacturers.

Additionally, it is projected that factors such as increased government attempts to lower the incidence of chronic diseases, rising awareness, and rising non-communicable disease prevalence in the region will fuel market expansion. For instance, the National Health Promotion Foundation tracks disease prevalence in South Africa and recommends ways to assist its decline. The market in this region is expected to increase due to several factors, including increasing health insurance penetration, rising public knowledge of available healthcare, various activities being carried out by different organizations, and privatization of healthcare.

Segmental Analysis

The global C reactive protein testing market is bifurcated into Assay Type, Detection Range, and Disease Area.

Based on the Assay Type, the global C reactive protein testing market is bifurcated into Immunoturbidimetric Assay, ELISA (Clinical, Non-Clinical), Chemiluminescence Immunoassay (CLIA), and Others.

The Immunoturbidimetric Assay segment dominates the global market and is projected to exhibit a CAGR of 0.3% over the forecast period. These tests for specific protein assays explain this segment's higher penetration. Routine biochemistry analyzers are fast, sensitive, cost-effective, and have prolonged reagent stability. Since analyte concentration is inversely proportional to the transmitted light signal, Randox Laboratories Ltd. recommends these systems for protein detection. POC devices based on this technique contribute significantly to the estimated share. Orion Diagnostical Oy's immunoturbidimetric-based Quick Read CRP kit quantifies CRP levels in plasma, serum, and whole blood samples. The organization built this primary health system to deliver results in minutes. Latex-enhanced, high-sensitivity immunoturbidimetric systems are available. Such field developments are predicted to affect growth in the future.

Field research will also boost the segment. For instance, high-sensitivity C-reactive protein tests in HIV patients showed that CRP can indicate HIV infection. HIV-infected people with elevated CRP had decreased vitamins and minerals. ELISA and immunoturbidimetric hsCRP tests can also detect low CRP levels. Immunoturbidimetric tests will rise due to technological advances. CRP assays for speedy and accurate detection are being developed worldwide. In January 2021, DM Vasudevan Agappe Diagnostic Limited, India researchers used a latex-enhanced immunoturbidimetric technique for high-sensitivity and wide-range CRP detection in human serum. Agappe Diagnostic Limited created a novel assay reagent. New items and advancements should boost market growth.

Based on application, the global C reactive protein testing market is bifurcated into Detection Ranges: hs-CRP, Conventional CRP, and CRP.

The hs-CRP segment owns the highest market share and is predicted to exhibit a CAGR of 0.29% over the forecast period. High-sensitivity CRP (hsCRP) testing overtook CRP testing. Hs-CRP tests are more accurate and have a lower detection range than CRP-based testing. High-sensitivity CRP detects 10 to >10.0 mg/L. hsCRP's independent marker status helps the AHA and CDC assess cardiovascular diseases, including myocardial infarction. Many regional probes are expected to push the segment. In treating Simvastatin and Ezetimibe in Aortic Stenosis (SEAS), a specific cardiovascular disorder, high-sensitivity CRP was a prognostic indicator in patients with mild to moderate aortic valve stenosis. The study also explained how lowering hsCRP levels increases cardiovascular disease risk. The Danish University of Copenhagen and other institutions conducted the study.

A recent study on inflammatory markers also discovered a link between elevated hsCRP levels and rheumatoid arthritis disease activity. The study found that a greater level of serum hsCRP might be used as a biomarker to identify the pathophysiology of rheumatoid arthritis. Additionally, it is anticipated that developing various hsCRP-based POC testing equipment by different market players will accelerate market expansion.

Based on Disease Area, the global C reactive protein testing market is bifurcated into Cardiovascular Diseases, Cancer, Rheumatoid arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others.

The Cardiovascular Diseases segment owns the highest market share and is predicted to exhibit a CAGR of 0.29% over the forecast period. The market for C-reactive protein testing is expanding mostly due to the rise in CVD prevalence. A few risk factors for CVDs include a sedentary lifestyle, obesity, hypertension, and diabetes. The most thoroughly investigated noninvasive biomarker for inflammation in CVDs is determined to be CRP, and there are already several hsCRP assays on the market. Numerous epidemiological studies have shown a connection between atherosclerosis and higher CRP plasma levels.

Cardiovascular disorders are among the leading causes of death worldwide, according to data from the WHO. About 17.9 million deaths globally in 2019 were attributed to cardiovascular illnesses, or 32% of all fatalities. 7.4 million people are estimated to have died from coronary heart disease, and 6.7 million from heart attacks. According to the WHO, heart attacks and strokes account for 85% of all deaths from cardiovascular disorders. In addition, the CDC reports that 805,000 Americans get a heart attack each year, and 655,000 Americans die from heart disease. Government initiatives and assistance are additional elements anticipated to propel the market. 

Based on End-Use, the global C reactive protein testing market is bifurcated into Clinics, Settings, Hospitals, Laboratories, Assisted Living, Healthcare Homes, and Others.

The hospital segment owns the highest market share and is predicted to exhibit a CAGR of 0.29% over the forecast period. The expansion of CRP testing in hospitals, particularly in developing nations worldwide, is responsible for the segment's growth. The prevalence of cardiovascular diseases and infections linked to cancer has increased, which has resulted in a rise in hospital visits and the use of CRP testing kits. This would give the market even more room to flourish. The usage of CRP testing kits in hospitals is also anticipated to increase due to partnerships between hospitals and private organizations. The popularity of CRP testing kits has increased due to increased hospital visits caused by COVID-19, cardiovascular diseases, and infections linked to cancer. This would give the market even more room to flourish.

Recent Developments

• November 2022- ProciseDx Inc. has announced that the FDA has cleared their ProciseDx instrument and C reactive Protein (CRP) test. Precise CRP quantitatively determines CRP levels in patient serum in less than 5 minutes. ProciseDx anticipates receiving FDA authorization for additional tests in 2023.
• November 2022- LumiraDx, a diagnostics testing company specializing in healthcare, has launched the C-Reactive Protein antigen test in India to tackle antibiotic resistance.